Hoth Therapeutics Stock Today
| HOTH Stock | USD 0.83 0.01 1.22% |
Performance4 of 100
| Odds Of DistressLess than 8
|
Hoth Therapeutics is trading at 0.83 as of the 21st of November 2024. This is a 1.22 percent increase since the beginning of the trading day. The stock's open price was 0.82. Hoth Therapeutics has only a 8 % chance of going through financial distress over the next few years but had a somewhat insignificant performance during the last 90 days. Equity ratings for Hoth Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 15th of February 2019 | Category Healthcare | Classification Health Care |
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York. Hoth Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.9 M outstanding shares of which 620.78 K shares are currently shorted by private and institutional investors with about 0.44 trading days to cover. More on Hoth Therapeutics
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Hoth Stock Highlights
| President, Founder | Robb Knie | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHoth Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hoth Therapeutics' financial leverage. It provides some insight into what part of Hoth Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Hoth Therapeutics (HOTH) is traded on NASDAQ Exchange in USA. It is located in 590 Madison Avenue, New York, NY, United States, 10022 and employs 2 people. Hoth Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.71 M. Hoth Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 6.9 M outstanding shares of which 620.78 K shares are currently shorted by private and institutional investors with about 0.44 trading days to cover.
Hoth Therapeutics currently holds about 11.62 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Hoth Therapeutics Probability Of Bankruptcy
Ownership AllocationRoughly 94.25 (percent) of Hoth Therapeutics outstanding shares are held by general public with 0.92 % owned by insiders and only 4.83 pct. by outside corporations.
Check Hoth Ownership Details
Hoth Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Armistice Capital, Llc | 2024-06-30 | 213 K | |
| Ubs Group Ag | 2024-06-30 | 43.4 K | |
| Vanguard Group Inc | 2024-09-30 | 38.8 K | |
| Geode Capital Management, Llc | 2024-06-30 | 35.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 20 K | |
| Tower Research Capital Llc | 2024-06-30 | 7.5 K | |
| Royal Bank Of Canada | 2024-06-30 | 240 | |
| Qube Research & Technologies | 2024-06-30 | 100.0 | |
| Bank Of America Corp | 2024-06-30 | 35.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 9.0 | |
| Wells Fargo & Co | 2024-06-30 | 2.0 |
Hoth Therapeutics Historical Income Statement
Hoth Stock Against Markets
Hoth Therapeutics Corporate Management
| Jane Springer | VP Operations | Profile | |
| Hayley Springer | Executive Operations | Profile | |
| Stefanie Johns | Chief Officer | Profile | |
| David Briones | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Return On Assets (0.46) | Return On Equity (0.83) |
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.